BIOGEN INC.
Company Information
Industry
Biological Products, (No Diagnostic Substances)
SIC Code
2836
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
225 BINNEY STREET, CAMBRIDGE, MA, 02142
Mailing Address
225 BINNEY STREET, CAMBRIDGE, MA, 02142
Phone
7814642000
Fiscal Year End
1231
EIN
330112644
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
Annual Reports
10-K
February 6, 2026
- Strategic acquisitions of Reata Pharmaceuticals ($7.3B) and Human Immunology Biosciences (initial $1.8B) are diversifying Biogen's pipeline into rare diseases and immunology.
- Successful initial revenue generation from new drug launches including SKYCLARYS ($150M), QALSODY ($20M), and ZURZUVAE ($10M) in 2024.
Material Events
8-K
Acquisition
March 31, 2026
High Impact
- Strategic acquisition of Apellis Pharmaceuticals for $7.8 billion to enter the high-growth specialty eye care market.
- Diversification beyond core neurology to mitigate patent expiration risks for flagship MS drugs.
8-K
Acquisition
January 14, 2026
High Impact
- Strategic decision to invest in future growth by expanding their research pipeline.
- Active efforts to bring new treatments to market, potentially leading to new treatment options for patients.
Insider Trading
SELL
2 insiders
3 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2836)
Scinai Immunotherapeutics Ltd.
SCNI
Biological Products, (No Diagnostic Substances)
Genenta Science S.p.A.
GNTA
Biological Products, (No Diagnostic Substances)
Greenland Mines Ltd
GRML
Biological Products, (No Diagnostic Substances)
Kymera Therapeutics, Inc.
KYMR
Biological Products, (No Diagnostic Substances)
Innate Pharma SA
IPHA
Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.